Discover more about Annogen and how we support the identification of regulatory DNA elements and non-coding genetic variants to help improve patient, plant, and animal health.
Events - Annogen attending BIOEurope in Munich, November 6–8, 2023
Request a partnering meeting with P. Victor Schut, CBO (firstname.lastname@example.org) and discuss the applications of:
- SuRE™ human promoters for cell and gene therapy
- CHO genome derived promoters for protein manufacturing, cell culture, and
- AIM™ integration site mapping for cell engineering (allogeneic, cell therapy and cell line generation).
Events - Annogen attending the virtual partnering at Alliance for Regenerative Medicine, October 17-18, 2023
Annogen plays a specific role in providing its SuRE™ human promoters (cell specific and/or inducible) and AIM™ integration mapping for cell engineering (e.g. allogeneic platforms).
Looking forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. Please contact (email@example.com) to learn more about the Annogen qualified promoters and cell engineering capabilities.
Events- March 2023 Annogen will be attending/partnering at the upcoming Cell and Gene Meeting on the Med
Looking forward to connecting with senior executives and top stakeholders and our partnering meetings. Please reach out through the partnering system or direct (firstname.lastname@example.org) to learn more about the Annogen qualified promoters and cell engineering capabilities.
NEWS- March 2023 Annogen enters Contract Manufacturing market:
AIM™ services and SuRE™ promoters
AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development.
Now it is also available to the contract manufacturing market: manufacturing virus and recombinant protein
Annogen (Amsterdam) is recruiting a
We are looking for someone who is enthusiastic about science and has a strong desire to contribute to cutting-edge research. As a Bioinformatician at our organization, you will be responsible for analysing complex biological data sets and developing and implementing computational methods for data analysis.
PRESS RELEASE - January 2023 Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments
PRESS RELEASE - December 2022 Annogen Announces Research Project with Pfizer to Test Non-coding Genetic Sequences
Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery.
NEWS - November 2022 Annogen introduces AIM™ service
Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its proprietary SuRE™ barcoding strategy and previously established protocols, Annogen has now scaled a gene-insertion and expression mapping strategy to unprecedented numbers.
PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Novel approach could aid selective breeding in cattle
Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical traits, such as productivity or disease tolerance, in livestock.
The study, involving Roslin researchers and their commercial partner Annogen, will focus on identifying sites in cattle DNA linked to important genes for livestock production and welfare.
NEWS – Annogen Featured in C2W
Many diseases are determined by differences in as yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome.
Read this article by Marysa van den Berg on the C2W website.
PRESS RELEASE – Amsterdam, 30 November 2021 Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants.
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen and KeyGene the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate in identifying non-coding DNA fragments in plants’ genomes that influence the expression of important crop traits. This will open new possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
Annogen incorporated to commercialize SuRE technology for Functional Genome Annotation.
Sister company Gen-X BV has just signed an exclusive deal for use of SuRE for gene therapy with uniQure and consequently, Annogen was incorporated with exclusive rights to commercialize the technology outside the gene therapy field.
February 1, 2020 - Annogen appoints Victor Schut as Chief Business Officer
After supporting sister company Gen-X as CBO in 2019 and following the recent execution of its exclusive deal with Dutch gene therapy company uniQure he will now focus on setting up the spin-off business around the SuRE technology outside the gene therapy field.